Medicineen
United Kingdom and United States Establish New Regulatory Reliance Pathway for Medical Devices
New international cooperation aims to accelerate patient access to innovative surgical and diagnostic technologies by streamlining approval processes.


PENN Explainer
Hear this story explained in 90 seconds.
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has officially launched new international reliance routes to expedite the approval of medical devices. This initiative allows the UK to leverage regulatory decisions made by trusted partners, specifically the United States Food and Drug Administration (FDA) and Canada’s Medical Devices Directorate. By recognizing approvals from these agencies, the UK aims to reduce the time it takes for life-saving technologies to reach patients within the National Health Service. The move is part of a broader effort to modernize the UK's regulatory framework and improve access to global medical innovations.
This policy shift follows extensive public consultation and feedback from stakeholders in the medical technology sector. Government officials emphasized that the new pathways are designed to eliminate unnecessary regulatory duplication that often slows the introduction of new products. By streamlining these processes, the MHRA can better focus its internal resources on scientific advice and regulatory activities that support the development of new products. The change is expected to benefit both patients and medical device manufacturers by creating a more efficient market entry process.
Lord Patrick Vallance, the Minister of State for Science, stated that the new international reliance routes are excellent news for patients who will now gain rapid access to new medical devices. He noted that these devices have already been approved as safe by trusted regulatory partners, making the streamlined approach a sensible decision. This strategy aligns with the UK's Life Sciences Sector Plan, which calls for the reduction of administrative burdens to foster innovation. The government views this as a critical step toward building a modern health service that is prepared for future challenges.
Medical experts have expressed support for the increased cooperation between international regulators. Lord Ara Darzi, a professor of surgery at Imperial College London, described the collaboration as a welcome step for surgical innovation. He highlighted that areas such as robotics, imaging, diagnostics, and artificial intelligence-enabled devices often face delays due to redundant regulatory requirements. According to Darzi, reducing these barriers will help close the gap between the approval of a device in one major market and its availability in another.
This regulatory alignment is part of a larger trend of international cooperation in the medical device sector. The announcement follows a preliminary understanding between the UK and the US regarding pharmaceutical pricing and market access. These agreements are intended to provide stronger incentives for companies to launch new treatments in the UK market. By reducing commercial risks, the UK hopes to attract more global investment in medical technology and pharmaceutical research.
While the new routes focus on efficiency, the MHRA maintains its commitment to safety and performance standards. The agency recently introduced new post-market surveillance requirements that took effect in June 2025. These rules mandate that manufacturers must proactively track the safety and performance of their products once they are on the market. This ensures that even with faster approval pathways, the long-term safety of patients remains a top priority for regulators.
The initiative also reflects a growing global consensus on the need for rigorous but efficient clinical investigation standards. Organizations like the European Society of Cardiology have recently advocated for more robust randomized clinical trials for high-risk devices. The UK's new reliance routes are designed to complement these high standards by ensuring that the data used for approval is both reliable and internationally recognized. This approach helps maintain public trust in the regulatory process while supporting the rapid adoption of new medical tools.
Looking ahead, the MHRA plans to continue its efforts to modernize the UK's regulatory landscape. The agency has indicated that it will consult later this year on the potential for the indefinite recognition of CE-marked medical devices. This would further integrate the UK market with international standards and provide more options for patients. These ongoing reforms are expected to keep the UK at the forefront of medical technology adoption.
The impact of these changes will be monitored closely by both the government and the medical community. As new devices move through these streamlined pathways, the focus will remain on delivering measurable clinical benefits to patients. The success of this program could serve as a model for other countries looking to balance the need for rapid innovation with the necessity of maintaining high safety standards. Ultimately, the goal is to ensure that patients have timely access to the most advanced medical care available globally.
You've reached your free article limit
You've read 10 of 10 free articles this month. Subscribe to Planet Earth News Network for unlimited access to neutral, global journalism — plus puzzles, podcasts, and the weekly newsletter.
Already a subscriber? Sign in.
Ask the Author
Subscribers can ask the journalist a question about this story. Subscribe to ask.
Neutrality note
Auto-harvested from global news wires and presented neutrally by PENN.
to vote
Comments
No comments yet — be the first to share your thoughts.



